AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06468436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-Esketamine Combination
Description: For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1.
Study NCT06468436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1.
Study NCT04890912 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionation
Description: Dose prescribed is 45 Gy in 25 fractions (1.8 Gy per fraction) delivered daily over 5 weeks.
Study NCT05704621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: secondary cytoreductive surgery
Description: Maximum effort cytoreductive surgery
Study NCT05704621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: six cycles of bevacizumab \[10 mg/kg, days 1 and 15\] plus carboplatin \[AUC 5, day 1\] plus pegylated liposomal doxorubicin \[30 mg/m2, day 1\] every 4 weeks, followed by maintenance bevacizumab \[15 mg/kg every 3 weeks\]
Study NCT05704621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: six cycles of bevacizumab \[10 mg/kg, days 1 and 15\] plus carboplatin \[AUC 5, day 1\] plus pegylated liposomal doxorubicin \[30 mg/m2, day 1\] every 4 weeks, followed by maintenance bevacizumab \[15 mg/kg every 3 weeks\]
Study NCT05069714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX-hold
Description: Temporary discontinuation of methotrexate for 1 or 2 weeks
Study NCT05069714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX-hold
Description: Temporary discontinuation of methotrexate for 1 or 2 weeks
Study NCT06229431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Carer Support Needs Assessment Tool Intervention (CSNAT-I)
Description: The CSNAT tool The tool includes 16 questions about the need for more support.~The five-stage person-centered approach~In the present study, the CSNAT-I consist of at least two meetings between the older spousal caregiver and the district nurse,1-4 weeks apart, following 5 stages:~1. Introduction of the CSNAT tool as a conversation starter.~2. Time for the spousal caregiver to consider the questions in which more support is needed.~3. An assessment conversation takes place.~4. A shared action plan is formed based on the assessment conversation.~5. Continuous shared review of the action plan.
Study NCT05192499 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stool test
Description: At inclusion (day 0), stools will be collected with a kit for to remove to 5 mg for each patient.
Study NCT05192499 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood test
Description: Blood sample taken during inclusion (day 0) will be collected. There is between 19 and 26 mL for each patient.
Study NCT05192499 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Induced sputum
Description: At inclusion (day 0), bronchial aspiration after inhalation induction of 4 mL of 6% salt serum administered (after 200 μg of salbutamol via an inhalation chamber during a bronchial drainage session).
Study NCT04890912 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Description: Dose prescribed is 30 Gy in 5 fractions (6 Gy per fraction) delivered every other day over 11 days. There will be a minimum of 36 hours and maximum of 96 hours between fractions. The entire course of treatment should be completed within no less than 10 days.
Study NCT05192499 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: nasale virology
Description: At inclusion (Day 0), patients will be taken nasal swab for virology with swab adapted for nasal swab or with suction trap when blowing the child's nose (depending on center practice)and multiplex PCR.
Study NCT06179628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low bolus concentration and volume
Description: Compare Low and Standard concentrations and volumes of bupivacaine boluses for continuous adductor block
Study NCT06179628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low bolus concentration and volume
Description: Compare Low and Standard concentrations and volumes of bupivacaine boluses for continuous adductor block
Study NCT05706883 — intervention group
Intervention type: PROCEDURE
Intervention: Needle or forceps biopsy of cervical and/or supraclavicular lymph nodes
Description: Patients with evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes suspected of being metastasis from lung cancer will be submitted to the biopsy from this location.
Study NCT05706883 — intervention group
Intervention type: PROCEDURE
Intervention: Needle, forceps or surgical biopsy of any lesion other than cervical and/or supraclavicular lymph nodes
Description: Patients without evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes will be submitted to the biopsy considered less invasive and effective based on imaging data and clinical health status.
Study NCT05123183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupressure group
Description: A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36 and CV17 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to CV17 point (single point) and ST36 point (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
Study NCT05123183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: back massage group
Description: The mother sits in the chair and leans forward, placing her arms on the table at her level and resting her head on her arms. The mother's breasts are naked and freely released. The researcher massages the mother from top to bottom on both sides of the spine between the scapula bones. At this time, his fists are clenched and the thumb is open. While pressing firmly with his fists, small circular friction movements are made with his thumb. From the neck to the scapula, both sides of the spine are rubbed at the same time for 3 minutes. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
Study NCT05123183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: No application will be made to the mothers in this group, and the amount of milk will be measured by weighing the baby before and after breastfeeding.
Study NCT05917600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APN intervention
Description: Advanced Practice Nurses (APN) intervention between the ambulatory hospitalization (AH) and the MD consultation~APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to.
Study NCT05614908 — intervention group
Intervention type: OTHER
Intervention: 11 week restrictive regime
Description: As part of standard care at AUH (until May 2024), patients are immobilized in scotch cast with the foot in plantarflexion during week 0-4. Next, the scotch cast is replaced by a ROM-WALKER in plantarflexion for the next 7 weeks (week 5-11 after injury). The ROM-WALKER is gradually corrected from 30 degrees plantarflexion to 0 degrees. No weight bearing or exercises is allowed and they are not allowed to remove the ROM-WALKER during week 0-10. At week 11, the patients are allowed weight bearing up to 30 kg, after which there is no longer weight bearing restrictions.~From week 12 they are allowed full weight bearing with a 1 cm heel lift i their shoes.
Study NCT05614908 — intervention group
Intervention type: OTHER
Intervention: 8 week liberal regime
Description: The patients are treated with a walker orthosis with 3 wedges in plantarflexion, during week 1-2 with no weight bearing and no exercises. After 2 weeks, the tendon will be examined, and if no defect in the tendon is detected by palpation, the patients will start partially weight bearing in week 3-5, and full weight-bearing week 6-8. They are instructed in unloaded exercises for the calf and anklejoint after 2 weeks, and loaded exercises (elastic) after 5 weeks, with a maximum position til 0 degrees in the anklejoint. Balancetraining and stationary bike training after 7 weeks. The wedges are removed one by one after 3, 5 and 7 weeks, respectively.~If there is a palpable defect in the tendon after 2 weeks, the patient must wait 1 week with partially weight bearing and exercises, and remove the wedges at 4, 5 and 7 weeks after the initiation of treatment.~From week 9, walking i their shoes with a 1 cm heel lift.
Study NCT05626374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Case Management plus rapid mental health & addictions healthcare access
Description: Usual case management support during 12-week training program plus rapid access referral process for healthcare crisis services
Study NCT05626374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Case Management plus Distress Tool and rapid mental health & addictions healthcare access
Description: Usual case management support during 12-week training program plus daily distress self-reports plus rapid access referral process for healthcare crisis services
Study NCT06117085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellFX® Percutaneous Electrode (PE) System
Description: Percutaneous treatment with CellFX® Percutaneous Electrode using nanosecond pulse field ablation (nsPFA) technology
Study NCT05990933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: Adrenaline infusion at a rate of 0.04ug/kg/min for 1 hour administered intravenously.
Study NCT05990933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline
Description: Adrenaline infusion at a rate of 0.04ug/kg/min for 1 hour administered intravenously.
Study NCT05836103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based intervention messages
Description: Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
Study NCT05276999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthcare provider education
Description: Mix of training and educational activities within the district continuing medical education system targeting community health workers and frontline providers focused on the importance of sore throat and it's link to RHD, clinical guidelines to differentiate patients at high or low risk for GAS pharyngitis and guideline based care for treating GAS pharyngitis
Study NCT05276999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Awareness campaign
Description: A district wide public health campaign to increase community awareness of sore throat, including school based education, VHT community sensitization, education of parents and patients, radio messaging, posters, signs and billboards.
Study NCT04842253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: HFNC during deep sedation undergoing radiofrequency ablation for atrial fibrillation.
Study NCT06161259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leritrelvir(Ray1216)
Description: Participants receive Leritrelvir orally.
Study NCT05299125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Low fucose, fully human immunoglobulin gamma-1-based bispecific antibody directed against EGFR and MET tyrosine kinase receptors. It shows clinical activity against tumors with the primary activating EGFR mutations Exon 19del or Exon 21 L858R substitution, EGFR Exon 20ins mutations, the EGFR resistance mutations Threonine790Methionine (T790M) or Cysteine797Serine (C797S), and activation of the Mesenchymal Epithelial Transition (MET) pathway.
Study NCT05299125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: It selectively inhibits both primary activating EGFR mutations (Exon 19del, Exon 21 L858R substitution) and the EGFR T790M resistance mutation, while having less activity versus wild-type EGFR.
Study NCT05299125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg
Description: Inhibits enzymes involved in folate-dependent metabolism, thereby disrupting cellular replication.
Study NCT05687591 — intervention group
Intervention type: DEVICE
Intervention: Amplatzer Amulet Left Atrial Appendage Occlusion Device
Description: The Amplatzer Amulet LAAO is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constucted from a nitinol mesh and consists of a lobe and a disc connected by a central waist. Polyester patches are sewn into both the lobe and disc to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires that permit visibility during fluoroscopy.
Study NCT04803357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: We are offering you an opportunity to wear a medical device that monitors your blood sugars (glucose). This device is called a continuous glucose monitor (CGM). The CGM measures glucose levels through a tiny plastic filament that is inserted under the skin in your abdomen by a skin prick. Typically, you cannot feel this device once it is inserted.
Study NCT05127005 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trapeziectomy
Description: Surgical excision of trapezoideum
Study NCT05127005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trapeziectomy
Description: Surgical excision of trapezoideum
Study NCT05127005 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Skin incision only
Study NCT05984732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminiscence with digital storytelling
Description: The older and young adult participants will be randomly assigned into the intervention (reminiscence) or control (social wellness) groups and then be randomly matched as dyads within each group. Older adults in the intervention group will receive 10 sessions of life-review with the trained young adult volunteers (1-1.5 hours each week for 10 weeks). During weeks 1-6, a life history interview will be carried out with different themes in each week: major turning points in life (W1), family history (W2), life/career accomplishments (W3), history of loves and hates (W4), stress experiences (W5), and meaning and purpose of life (W6). During weeks 7-10, the dyads will develop the DST together using tablets already owned by the UTA School of Social Work. The contents of sessions 7-10 will be structured as: outline/script, plan and storyboard (W7), film and record (W8), evaluate, integrate and finalize (W9), and publish/share (W10).
Study NCT05984732 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Social wellness with scrapbook or journal
Description: Older adults in the control group will have general social wellness discussion with the young adult volunteers, instead of structured reminiscence guidelines. The topics are: diet and health (week 1); exercise/activity and health (week 2); emotions and health (week 3); religious/spiritual practices and health (week 4); family/friend relationships and health (week 5); and social activities/engagement and health (week 6). For weeks 7-10, instead of DST, the young adult volunteer will work with the older adult to create an unstructured, non-digital record of the social visit related to wellness in later life (e.g. wellness scrapbook/journal).
Study NCT06463210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality as a distraction technique
Description: A 360º relaxing video with music was displayed through a VR headset
Study NCT05186064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: whole genome sequencing
Description: whole genome sequencing will be performed on tumor material after re-resection per standard of care
Study NCT05884723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: 4-week preoperative well-formulated very low carbohydrate isocaloric diet consisting of 50g net daily carbohydrates and 1.5g/kg protein with the remaining energy needs consisting of primarily mono- and polyunsaturated fats
Study NCT05659095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous hair follicle derived mesenchymal stem cell suspension
Description: Healthy hair follicles were extracted from the occipital area and treated to obtain hair follicle mesenchymal stem cells suspensions. The recipient sites were divided into two groups. Nine points were injected in a 1 cm2 area, and 100 μl of solution containing either 1 × 105 cells or normal saline was injected at each point. The follow-up duration was 9 months.
Study NCT05827523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75mg/m2 after interval cytoreductive surgery
Study NCT03902067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSC
Description: 0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability>80%, and endotoxin\<0.1 EU， at the concentration of 2x10(7) cells/ml.
Study NCT03902067 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Routine treatment without catheter infusion
Study NCT06037291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coriander Seed Oil
Description: The study foresees the intake of 1 capsule per day during 56 days
Study NCT06037291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study foresees the intake of 1 capsule per day during 56 days
Study NCT04801160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REMS+TAI
Description: Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
Study NCT04801160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SEMS+TAI
Description: Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
Study NCT06386302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30 mg/d orally twice-weekly
Study NCT06386302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 100 mg d1 200 mg d 2 400 mg d3-d28 Orally
Study NCT06386302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: 100 mg d1 200 mg d 2 400 mg d3-d28 Orally
Study NCT06386302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: 75 mg/m 2 /d subcutaneous injection or IV d1-d7
Study NCT06386302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azacitidine
Description: 75 mg/m 2 /d subcutaneous injection or IV d1-d7